Cargando…

Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review

Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm that was classified by the World Health Organization (WHO) under histiocytic and dendritic cell neoplasms in the 2016 revision. Considering the rarity of this tumor, there is no standardized treatment. It is usually treated by com...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Nanxiang, Ba, Wei, Zhao, Dawei, Sheng, Lei, Zhang, Xinxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922364/
https://www.ncbi.nlm.nih.gov/pubmed/35299752
http://dx.doi.org/10.3389/fonc.2022.816903
_version_ 1784669510347784192
author Chen, Nanxiang
Ba, Wei
Zhao, Dawei
Sheng, Lei
Zhang, Xinxin
author_facet Chen, Nanxiang
Ba, Wei
Zhao, Dawei
Sheng, Lei
Zhang, Xinxin
author_sort Chen, Nanxiang
collection PubMed
description Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm that was classified by the World Health Organization (WHO) under histiocytic and dendritic cell neoplasms in the 2016 revision. Considering the rarity of this tumor, there is no standardized treatment. It is usually treated by complete surgical resection. Adjuvant chemotherapy and radiotherapy are alternative methods. Immune checkpoint inhibitors (ICIs) represented by the programmed death receptor 1/programmed death ligand 1 (PD-1/PD-L1) antibody have achieved significant clinical benefits in a variety of solid tumors. However, reports on the treatment of FDCS with ICIs are rare. FDCS often expresses high levels of PD-L1, which provides a rationale to use immunotherapy in cases of FDCS. Here, we present a 51-year-old Filipino-Chinese man with FDCS who was treated with multimodal treatment, including the PD-1 inhibitor pembrolizumab and achieved a relatively long disease-free survival of 24 months. This case emphasizes that the application of ICIs under the guidance of NGS technology seems to be a meaningful treatment option for patients with FDCS.
format Online
Article
Text
id pubmed-8922364
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89223642022-03-16 Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review Chen, Nanxiang Ba, Wei Zhao, Dawei Sheng, Lei Zhang, Xinxin Front Oncol Oncology Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm that was classified by the World Health Organization (WHO) under histiocytic and dendritic cell neoplasms in the 2016 revision. Considering the rarity of this tumor, there is no standardized treatment. It is usually treated by complete surgical resection. Adjuvant chemotherapy and radiotherapy are alternative methods. Immune checkpoint inhibitors (ICIs) represented by the programmed death receptor 1/programmed death ligand 1 (PD-1/PD-L1) antibody have achieved significant clinical benefits in a variety of solid tumors. However, reports on the treatment of FDCS with ICIs are rare. FDCS often expresses high levels of PD-L1, which provides a rationale to use immunotherapy in cases of FDCS. Here, we present a 51-year-old Filipino-Chinese man with FDCS who was treated with multimodal treatment, including the PD-1 inhibitor pembrolizumab and achieved a relatively long disease-free survival of 24 months. This case emphasizes that the application of ICIs under the guidance of NGS technology seems to be a meaningful treatment option for patients with FDCS. Frontiers Media S.A. 2022-03-01 /pmc/articles/PMC8922364/ /pubmed/35299752 http://dx.doi.org/10.3389/fonc.2022.816903 Text en Copyright © 2022 Chen, Ba, Zhao, Sheng and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chen, Nanxiang
Ba, Wei
Zhao, Dawei
Sheng, Lei
Zhang, Xinxin
Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review
title Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review
title_full Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review
title_fullStr Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review
title_full_unstemmed Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review
title_short Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review
title_sort response of tonsil follicular dendritic cell sarcoma to multimodal treatment including pembrolizumab: a case report and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922364/
https://www.ncbi.nlm.nih.gov/pubmed/35299752
http://dx.doi.org/10.3389/fonc.2022.816903
work_keys_str_mv AT chennanxiang responseoftonsilfolliculardendriticcellsarcomatomultimodaltreatmentincludingpembrolizumabacasereportandliteraturereview
AT bawei responseoftonsilfolliculardendriticcellsarcomatomultimodaltreatmentincludingpembrolizumabacasereportandliteraturereview
AT zhaodawei responseoftonsilfolliculardendriticcellsarcomatomultimodaltreatmentincludingpembrolizumabacasereportandliteraturereview
AT shenglei responseoftonsilfolliculardendriticcellsarcomatomultimodaltreatmentincludingpembrolizumabacasereportandliteraturereview
AT zhangxinxin responseoftonsilfolliculardendriticcellsarcomatomultimodaltreatmentincludingpembrolizumabacasereportandliteraturereview